Priovant Therapeutics joins MSU to discuss The Valor Study for Dermatomyositis, a phase 3 clinical trial for Adult Dermatomyositis....
IVIg Proves Effective for Dermatomyositis in Phase 3 Trial
, , Dermatomyositis, Featured, Myositis Treatments
The study provided efficacy data for Octagam 10%, which was approved for dermatomyositis by the US Food and Drug...
If you are living with dermatomyositis, polymyositis, or antisynthetase syndrome, join the third Wednesday of each month for...
The VALOR Study – New Clinical Research Opportunity for Dermatomyositis
, , Dermatomyositis, Featured, Video
We hosted Priovant Therapeutics to discuss The Valor Study, a phase 3 clinical trial for adult dermatomyositis. Learn all...
Please join us for a webinar about the new VALOR study. The purpose of the VALOR Study is to...
Dermatomyositis and Sun Protection, Dr. Graham makes it clear the sun can cause flares. She talks about sunscreens and...
Dr. Graham educates about the skin manifestations of myositis, sharing the various DM rashes, cosmetic cover-ups, information and tips...
Co-authors of “Pain profile and opioid medication use in patients with idiopathic inflammatory myopathies”, published in Rheumatology discuss the...
The Power of Our Voice: FDA Listening Session for Adult DM Webinar
, , Dermatomyositis, Featured, News, Video
Watch the recording of our fireside chat, The Power of Our Voice: FDA Listening Session for Adult Dermatomyositis, where...
View the summary of our first-ever FDA Listening Session on Adult Dermatomyositis. This was an opportunity to facilitate the...
Watch the recording with Alexion Pharmaceuticals to learn about the Flex Study to evaluate the safety and efficacy of...
Join MSU with Sanjay Rakhade MD, PhD, Executive Medical Director at Alexion Astra Zeneca Rare Disease Unit to learn...
Intravenous Immune Globulin (IVIg) – A newly approved therapeutic option for the treatment of adult dermatomyositis
, , Featured, Myositis Treatments, Research
Watch to learn about Octapharma’s IVIg therapy and the results of the landmark Progress in Dermatomyositis (ProDERM) study. The...
Intravenous Immune Globulin (IVIg) – A newly approved therapeutic option for the treatment of adult dermatomyositis
,
Learn about Octapharma’s IVIg therapy and the results of the landmark Progress in Dermatomyositis (ProDERM) study. The successful ProDERM...
Watch Poor Long-term Clinical Outcomes and Health-Related Quality of Life in Dermatomyositis and Polymyositis
, , Featured, Research
Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune inflammatory myopathies characterized by muscle weakness and multiple extra-muscular manifestations that...
Poor Long-term Clinical Outcomes and Health-Related Quality of Life in Dermatomyositis and Polymyositis
,
Register and join us on Rare Disease Day, Feb. 28th, for a presentation by Dr. Rohit Aggarwal reviewing current...
MSU is hosting the first FDA Listening Session on Adult Dermatomyositis on April 26, 2022. We hope the FDA will come...
AllStripes was honored to host this webinar with the Myositis Support and Understanding Association to discuss our current and...
Are you interested in advancing research for dermatomyositis? Join us on Friday, December 3rd at 3 PM EST for...
Seeking ten (10) people living with Dermatomyositis who would be willing to share their personal experience in a market...
